Athira Pharma (ATHA) Stock Price, News & Analysis

Company Overview

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Key Stats

• Today's Range: $0.38 to $0.41
• 50-Day Range: $0.30 to $0.49
• 52-Week Range: $0.22 to $3.51
• Volume: 90,068 shs
• Average Volume: 154,348 shs
• Market Capitalization: $15.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.50
• Consensus Rating: Hold

Athira Pharma Stock Analysis - MarketRank™

Athira Pharma scored higher than 63% of companies evaluated by MarketBeat, and ranked 375th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Athira Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Athira Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Athira Pharma are expected to grow in the coming year, from ($2.35) to ($0.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Athira Pharma is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Athira Pharma is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Athira Pharma has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.80% of the float of Athira Pharma has been sold short.

Short Interest Ratio / Days to Cover

Athira Pharma has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Athira Pharma has recently decreased by 8.22%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Athira Pharma does not currently pay a dividend.

Dividend Growth

Athira Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.80% of the float of Athira Pharma has been sold short.

Short Interest Ratio / Days to Cover

Athira Pharma has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Athira Pharma has recently decreased by 8.22%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Athira Pharma this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for ATHA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Athira Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Athira Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,743.00 in company stock.

Percentage Held by Insiders

22.10% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ATHA Stock Analysis - Frequently Asked Questions

How have ATHA shares performed this year?

Athira Pharma's stock was trading at $0.5867 at the beginning of the year. Since then, ATHA shares have decreased by 32.1% and is now trading at $0.3985.

How were Athira Pharma's earnings last quarter?

Athira Pharma, Inc. (NASDAQ:ATHA) issued its earnings results on Thursday, August, 7th. The company reported ($0.18) earnings per share for the quarter, hitting the consensus estimate of ($0.18).

When did Athira Pharma IPO?

Athira Pharma (ATHA) raised $160 million in an initial public offering on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel served as the underwriters for the IPO and JMP Securities was co-manager.

Who are Athira Pharma's major shareholders?

Top institutional shareholders of Athira Pharma include BML Capital Management LLC (8.27%) and Qube Research & Technologies Ltd (0.49%). Insiders that own company stock include Perceptive Advisors Llc, Mark James Litton, Glenna Mileson, Mark Worthington, Robert Renninger, Kelly A Romano, Hans Moebius, Rachel Lenington and James A Johnson.
View institutional ownership trends.

How do I buy shares of Athira Pharma?

Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Athira Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Athira Pharma investors own include Pfizer (PFE), PayPal (PYPL), Advanced Micro Devices (AMD), Alibaba Group (BABA), Intel (INTC) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/20/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATHA
• CIK: 1620463
• Web: athira.com
• Phone: 425-620-8501
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Athira Pharma: $0.50
• High Price Target: $0.50
• Low Price Target: $0.50
• Potential Upside/Downside: +25.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$96.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -139.40%
• Return on Assets: -106.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.81
• Quick Ratio: 10.81

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.81 per share
• Price / Book: 0.49

Miscellaneous

• Outstanding Shares: 39,440,000
• Free Float: 30,723,000
• Market Cap: $15.72 million
• Optionable: Optionable
• Beta: 3.00